Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 29, 2022
Reporting Period: Single event date (November 29, 2022)
Business Context: The Company is an emerging growth company incorporated in Nevada, with its principal executive offices in Boca Raton, FL. Its common stock trades on the NASDAQ under the symbol "INMB".
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
No material financial changes or operational updates were reported in this filing. The document solely discloses the Company's scheduled participation in an upcoming industry conference.
Guidance, Outlook, and Events
- Corporate Event: On November 29, 2022, the Company announced its participation in the 15th CTAD Conference.
- Event Details: The conference is scheduled to take place in San Francisco from November 29 to December 2, 2022.
- Management Commentary: No specific guidance, outlook, or management commentary regarding financial performance or strategic direction was included in this report.
- Risks and Contingencies: No new risks or contingencies were disclosed in this filing.
Investor Verification Checklist
- Verify the content of the press release attached as Exhibit 99.1 for specific details on the Company's presentation at the CTAD Conference.
- Review the Company's most recent 10-Q or 10-K filing for actual financial performance data, as this 8-K contains no financial figures.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting standards.